Skip to Main Content

Paper Details

Combined HAT/EZH2 modulation leads to cancer-selective cell death.
Oncotarget
4
2018
BCL-2, BCL2, BCL2 promoter, EZH2, H3K27ac, H3K27me3, H3K9, HAT, MC2884, TET2, TP53, TP53 or TET2-deficient human cancers, cancer, caspase, cleaved-BID, epigenome, human, human primary leukemia blasts, p300, p53, p53-/- or TET2-/- cells, solid and hematological cancers, xenograft models
Author NameAffiliation
Colin LogieRadboud University
Simon Heath
Simon Heath
Paul FlicekEuropean Bioinformatics Institute
Paul FlicekEuropean Bioinformatics Institute
Marie-Laure YaspoMax Planck Institute for Molecular Genetics
Ivo Gut
Hendrik G StunnenbergRadboud University
Joost H A MartensRadboud University
Joost H A MartensUniversita degli Studi della Campania Luigi Vanvitelli
  • 1 - 10

Datasets

Release 1.2